Photo from wikipedia
Mucocutaneous ulceration is one of the hallmark manifes-tations of Behçet’s disease (BD). Interleukin-17A (IL-17A) inhibitors have been indicated in mucocutaneous lesions refractory to conventional therapy in patients with BD (1).… Click to show full abstract
Mucocutaneous ulceration is one of the hallmark manifes-tations of Behçet’s disease (BD). Interleukin-17A (IL-17A) inhibitors have been indicated in mucocutaneous lesions refractory to conventional therapy in patients with BD (1). IL-17A inhibitors have also proved to be an effective therapeutic approach for psoriasis (2). The potential therapeutic effects on other inflammatory cutaneous conditions are also being explored (3). However, here, we report a case in which IL-17A inhibition with ixekizumab paradoxically induced ulcerative mucocutaneous lesions typically seen in BD.
Journal Title: Scandinavian Journal of Rheumatology
Year Published: 2022
Link to full text (if available)
Share on Social Media: Sign Up to like & get
recommendations!